HomeTrialNCT06037252
🔬NCT06037252Phase 2ACTIVE NOT RECRUITING

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Study Summary

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment414 participants
Primary Completion
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.866304+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.